Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.
YTR 830, a new beta-lactamase inhibitor, was compared with clavulanic acid and sulbactam against aminopenicillin-resistant clinical isolates. At a concentration of 8 micrograms/ml, YTR 830 was as effective as clavulanate or sulbactam in reducing the aminopenicillin MICs. Combined with amoxicillin, YTR 830 is a potentially useful agent for therapy of many bacterial infections.
D000658:Amoxicillin / Q000494:pharmacology*; D000667:Ampicillin / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D019818:Clavulanic Acid; D002969:Clavulanic Acids / Q000494:pharmacology*; D004338:Drug Combinations; D010397:Penicillanic Acid / Q000494:pharmacology*; D013407:Sulbactam; D000078142:Tazobactam; D065093:beta-Lactamase Inhibitors
D002969:Clavulanic Acids; D004338:Drug Combinations; D065093:beta-Lactamase Inhibitors; D019818:Clavulanic Acid; D000667:Ampicillin; D000658:Amoxicillin; D010397:Penicillanic Acid; D013407:Sulbactam; D000078142:Tazobactam